Aurinia Pharmaceuticals Inc. announced that for fiscal year 2022, the Company is providing net revenue guidance of $115 million to $135 million from sales of LUPKYNIS. This range is based on assumptions regarding the impact of COVID-19 on the current business environment and represents an increase of more than 150% to 200% in net revenue from sales of LUPKYNIS compared to fiscal year 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.62 USD | +2.00% |
|
+2.93% | -37.49% |
Jun. 14 | Declaration of Voting Results by Aurinia Pharmaceuticals | CI |
Jun. 14 | Declaration of Voting Results by Aurinia Pharmaceuticals Inc | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.49% | 786M | |
+16.13% | 122B | |
+19.65% | 115B | |
+21.22% | 26.64B | |
-23.84% | 19.91B | |
-17.47% | 16.32B | |
-45.95% | 15.52B | |
-19.28% | 15.49B | |
+63.81% | 14.83B | |
+1.94% | 13.67B |
- Stock Market
- Equities
- AUPH Stock
- News Aurinia Pharmaceuticals Inc.
- Aurinia Pharmaceuticals Inc. Provides Revenue Guidance for the Year 2022